August 1, 2024
Letter to our community from Spark Therapeutics
The IPA has been informed that Spark Therapeutics has realigned its portfolio and made the difficult decision to stop its Pompe program. This includes the Phase 1/2 Investigational Gene Transfer Study, Resolute, for Adults with Late-Onset Pompe Disease (LOPD).
Spark Therapeutics Stops Its Pompe Program – International Pompe Association (worldpompe.org)